Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Director Gordon R. Bernard Sells 1,859 Shares

Share on StockTwits

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Director Gordon R. Bernard sold 1,859 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $6.24, for a total value of $11,600.16. Following the completion of the sale, the director now owns 95,388 shares of the company’s stock, valued at $595,221.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Shares of Cumberland Pharmaceuticals stock opened at $6.30 on Monday. The company has a market capitalization of $97.88 million, a P/E ratio of -52.50 and a beta of 0.14. Cumberland Pharmaceuticals, Inc. has a fifty-two week low of $4.83 and a fifty-two week high of $7.00. The company has a quick ratio of 1.67, a current ratio of 2.07 and a debt-to-equity ratio of 0.36.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.22. The company had revenue of $11.90 million during the quarter, compared to analyst estimates of $10.70 million. Cumberland Pharmaceuticals had a positive return on equity of 2.54% and a negative net margin of 10.57%. Equities research analysts predict that Cumberland Pharmaceuticals, Inc. will post 0.28 EPS for the current year.

A number of equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded Cumberland Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.00 price target for the company in a research report on Friday, May 17th. TheStreet upgraded Cumberland Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Wednesday, April 10th.

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Stonepine Capital Management LLC lifted its stake in Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) by 7.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,313,429 shares of the specialty pharmaceutical company’s stock after buying an additional 95,028 shares during the quarter. Cumberland Pharmaceuticals makes up 7.0% of Stonepine Capital Management LLC’s holdings, making the stock its 4th largest position. Stonepine Capital Management LLC owned about 8.46% of Cumberland Pharmaceuticals worth $7,920,000 as of its most recent filing with the Securities & Exchange Commission. 31.72% of the stock is currently owned by institutional investors and hedge funds.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Recommended Story: Why is the price-sales ratio important?

Insider Buying and Selling by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Elastic  Rating Lowered to Sell at Zacks Investment Research
Elastic Rating Lowered to Sell at Zacks Investment Research
Diplomat Pharmacy  Stock Rating Lowered by Zacks Investment Research
Diplomat Pharmacy Stock Rating Lowered by Zacks Investment Research
Dicerna Pharmaceuticals  Rating Lowered to Sell at Zacks Investment Research
Dicerna Pharmaceuticals Rating Lowered to Sell at Zacks Investment Research
Eastgroup Properties  Rating Lowered to Hold at Zacks Investment Research
Eastgroup Properties Rating Lowered to Hold at Zacks Investment Research
Zacks Investment Research Upgrades NOW  to “Buy”
Zacks Investment Research Upgrades NOW to “Buy”
Zacks Investment Research Downgrades Endologix  to Hold
Zacks Investment Research Downgrades Endologix to Hold


© 2006-2019 Ticker Report